Theravance Biopharma discloses separation terms for departing CFO Andrew Hindman

Theravance Biopharma, Inc.

Separation agreement includes lump sum of 24 weeks base salary and 100% of 2022 target cash bonus.
Company to pay up to 9 months COBRA premiums.
20,000 performance-based RSUs vested (performance criteria met).
Hindman eligible for change in control severance if change in control within 3 months after Dec 31, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Hindman

Chief Financial Officer

TBPH · Theravance Biopharma, Inc.

Filed: March 1, 2023, 6:59 PM ET

On January 10, 2023, Theravance Biopharma US, Inc., a wholly owned subsidiary of the Company (“Theravance Biopharma US”), and Mr. Hindman entered into a separation agreement and release of claims (the “Separation Agreement”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Hindman departed as Chief Financial Officer at Theravance Biopharma, Inc..

Action: separated
Role: Chief Financial Officer

Exact text from the filing

On January 10, 2023, Theravance Biopharma US, Inc., a wholly owned subsidiary of the Company (“Theravance Biopharma US”), and Mr. Hindman entered into a separation agreement and release of claims (the “Separation Agreement”).

View on SEC.gov

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-027339

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.